Vault-13

Aquilo Capital Management, LLC

SAN FRANCISCO, CA · CIK 1591986 · 13F filing filed 2022-02-14

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$406.7m reported value -4.3% vs Q3 2021
13positions
93.9%in top 10
1 new 7 added 1 reduced 1 sold out vs Q3 2021

Options: 0 call positions (— notional), 1 put positions ($475.0m notional) – listed below, not included above.

Holdings, Q4 2021

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 SPERO THERAPEUTICS INC COM SPRO SPRO 4,964,181 $79.5m19.54% 19.54% AddedShares held: Q1 2021 3.8m, Q2 2021 3.8m, Q3 2021 4.6m, Q4 2021 5.0m +400.5k +400,493 8.8%
2 BLUEPRINT MEDICINES CORP COM BPMC BPMC 645,539 $69.1m17.00% 17.00% AddedShares held: Q1 2021 423.0k, Q2 2021 448.5k, Q3 2021 521.7k, Q4 2021 645.5k +123.9k +123,866 23.7%
3 ARROWHEAD PHARMACEUTICALS IN COM ARWR ARWR 700,426 $46.4m11.42% 11.42% AddedShares held: Q1 2021 407.9k, Q2 2021 432.9k, Q3 2021 527.9k, Q4 2021 700.4k +172.5k +172,500 32.7%
4 ARVINAS INC COM ARVN ARVN 563,451 $46.3m11.38% 11.38% AddedShares held: Q1 2021 0, Q2 2021 0, Q3 2021 354.7k, Q4 2021 563.5k +208.7k +208,740 58.9%
5 REGENXBIO INC COM RGNX RGNX 1,013,596 $33.1m8.15% 8.15% AddedShares held: Q1 2021 559.4k, Q2 2021 595.4k, Q3 2021 839.1k, Q4 2021 1.0m +174.5k +174,457 20.8%
6 4D MOLECULAR THERAPEUTICS IN COM FDMT FDMT 1,509,944 $33.1m8.14% 8.14% AddedShares held: Q1 2021 300.9k, Q2 2021 945.4k, Q3 2021 1.1m, Q4 2021 1.5m +410.0k +410,000 37.3%
7 MERUS N V COM MRUS MRUS 896,502 $28.5m7.01% 7.01% NewShares held: Q1 2021 0, Q2 2021 0, Q3 2021 0, Q4 2021 896.5k
8 AMRYT PHARMA PLC SPONSORED ADS SPONSORED ADS 1,640,000 $17.7m4.35% 4.35% AddedShares held: Q1 2021 800.0k, Q2 2021 1.1m, Q3 2021 1.4m, Q4 2021 1.6m +250.0k +250,000 18.0%
9 UNIQURE NV SHS QURE QURE 676,206 $14.0m3.45% 3.45% ReducedShares held: Q1 2021 955.4k, Q2 2021 1.2m, Q3 2021 1.3m, Q4 2021 676.2k -643.3k -643,307 -48.8%
10 MAGENTA THERAPEUTICS INC COM COM 3,155,082 $14.0m3.44% 3.44% UnchangedShares held: Q1 2021 2.5m, Q2 2021 2.7m, Q3 2021 3.2m, Q4 2021 3.2m
11 PIERIS PHARMACEUTICALS INC COM COM 3,196,527 $12.1m2.97% 2.97% UnchangedShares held: Q1 2021 3.7m, Q2 2021 3.2m, Q3 2021 3.2m, Q4 2021 3.2m
12 ARGENX SE SPONSORED ADR ARGX ARGX 22,200 $7.8m1.91% 1.91% UnchangedShares held: Q1 2021 21.2k, Q2 2021 21.2k, Q3 2021 22.2k, Q4 2021 22.2k
13 GENMAB A/S SPONSORED ADS GMAB GMAB 127,500 $5.0m1.24% 1.24% UnchangedShares held: Q1 2021 120.0k, Q2 2021 120.0k, Q3 2021 127.5k, Q4 2021 127.5k

Sold out since Q3 2021

SecurityTickerShares held beforeValue then
DICERNA PHARMACEUTICALS INC DRNA DRNA 2,456,595 $49.5m2.5m shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
SPDR S&P 500 ETF TR SPY · Put SPYPut 1,000,000 $475.0m1.0m shares New

Trades reported as a company insider in Q4 2021

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2021-12-31 SPERO THERAPEUTICS INC 10% owner · See Footnotes SPRO Bought 125,000 $2.0m125.0k shares +3%
2021-12-30 SPERO THERAPEUTICS INC 10% owner · See Footnotes SPRO Bought 50,000 $788.5k50.0k shares +1%
2021-12-29 SPERO THERAPEUTICS INC 10% owner · See footnotes SPRO Bought 75,493 $1.1m75.5k shares +2%
2021-10-29 SPERO THERAPEUTICS INC 10% owner · See Footnotes SPRO Bought 150,000 $2.6m150.0k shares +3%